Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1986 Nov;22(5):565-70.
doi: 10.1111/j.1365-2125.1986.tb02936.x.

The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine

Clinical Trial

The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine

V Challenor et al. Br J Clin Pharmacol. 1986 Nov.

Abstract

The pharmacokinetics of a novel 20 mg biphasic release tablet of nifedipine were compared with the conventional 10 mg capsule and 20 mg sustained release preparations in healthy volunteers. The influence of food and posture on the pharmacokinetics of the biphasic tablet were studied. In the fasting state, the time to peak concentration of nifedipine was not significantly different between the 20 mg biphasic and 20 mg sustained release tablets, but plasma concentrations were higher between 2 and 4 h after the biphasic tablet. The terminal elimination half-lives of the two formulations were similar. In subjects who fed prior to nifedipine administration there was no significant difference between either the peak plasma concentration or terminal half-life of the biphasic tablet and two 10 mg capsules of nifedipine. When the biphasic preparation was given after a standard breakfast, the time to peak plasma concentration was significantly longer and the terminal half-life shorter than when given in the fasting state. The dissolution characteristics of the biphasic tablet were influenced by prior administration of food to an extent which may be of clinical significance during twice daily administration.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Clin Pharmacokinet. 1979 Nov-Dec;4(6):433-48 - PubMed
    1. J Cardiovasc Pharmacol. 1985 Jan-Feb;7(1):12-7 - PubMed
    1. Br Med J. 1980 Jul 19;281(6234):184-7 - PubMed
    1. Br J Clin Pharmacol. 1979 Jul;8(1):7-20 - PubMed
    1. Am J Med. 1981 Oct;71(4):645-57 - PubMed

Publication types